pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer

被引:0
|
作者
Jansen, RLH
Hupperets, PSGJ
Arends, JW
Joosten-Achjanie, SR
Volovics, A
Hillen, HFP
Schouten, HC
机构
[1] Univ Hosp Maastricht, Dept Internal Med, Div Haematol Oncol, NL-6202 AZ Maastricht, Netherlands
[2] Univ Hosp Maastricht, Dept Pathol, NL-6202 AZ Maastricht, Netherlands
[3] Univ Maastricht, Dept Methodol & Stat, Maastricht, Netherlands
关键词
pS2; breast cancer; prognostic factor; post-relapse survival;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The pS2 protein is involved in the maintenance of the integrity of the gastrointestinal tract. In breast cancer pS2 can be demonstrated in at least half of the tumors and probably reflects the functional status of ER Several features make it likely that pS2 is involved in growth regulation. patients and Methods: I;Ve have investigated the value of immunohistochemical pS2 determination as a prognostic factor in 339 breast cancer patients with long follow-up from one hospital Results: A prognostic role for pS2 could not be demonstrated considering disease-free and overall survival, although in pS2-negative tumors a trend for less locoregional relapse was found. However, in multivariate analysis pS2 showed independent prognostic value for post-relapse survival. Conclusions: PS2 is an independent prognostic factor for post-relapse survival, most likely because a is a predictive factor for response to systemic therapy.
引用
收藏
页码:577 / 582
页数:6
相关论文
共 50 条
  • [21] IMMUNOHISTOCHEMICAL DIAGNOSIS AND EVALUATION OF THE PROGNOSTIC-SIGNIFICANCE OF PS2 PROTEIN IN BREAST-CANCER
    BECKMANN, MW
    CAMINADA, MC
    GOHRING, UJ
    SCHARL, A
    TUTSCHEK, B
    BENDER, HG
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 803 - 804
  • [22] Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer
    Span, PN
    Manders, P
    Heuvel, JJ
    Thomas, CMG
    Bosch, RR
    Beex, LV
    Sweep, CGJ
    ONCOGENE, 2002, 21 (55) : 8506 - 8509
  • [23] Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score
    Seebacher, Veronika
    Sturdza, Alina
    Bergmeister, Birgit
    Polterauer, Stephan
    Grimm, Christoph
    Reinthaller, Alexander
    Hilal, Ziad
    Aust, Stefanie
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2019, 299 (04) : 1055 - 1062
  • [24] ESTRADIOL RECEPTOR IN PRIMARY BREAST-CANCER - AN INDEPENDENT PROGNOSTIC FACTOR
    BLAMEY, RW
    MAYNARD, PV
    DAVIES, CJ
    ELSON, CW
    JOHNSTON, J
    GRIFFITHS, K
    BISHOP, H
    BRITISH JOURNAL OF SURGERY, 1978, 65 (11) : 822 - 822
  • [25] Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score
    Veronika Seebacher
    Alina Sturdza
    Birgit Bergmeister
    Stephan Polterauer
    Christoph Grimm
    Alexander Reinthaller
    Ziad Hilal
    Stefanie Aust
    Archives of Gynecology and Obstetrics, 2019, 299 : 1055 - 1062
  • [26] p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer
    Hiroko Yamashita
    Tatsuya Toyama
    Mariko Nishio
    Yoshiaki Ando
    Maho Hamaguchi
    Zhenhuan Zhang
    Shunzo Kobayashi
    Yoshitaka Fujii
    Hirotaka Iwase
    Breast Cancer Research, 8
  • [27] Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Ogiya, Akiko
    Yamazaki, Kieko
    Horii, Rie
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Hosoda, Mitsuchika
    Ishida, Naoko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    Yamashita, Hiroko
    BREAST CANCER, 2017, 24 (03) : 473 - 482
  • [28] Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Akiko Ogiya
    Kieko Yamazaki
    Rie Horii
    Tadahiko Shien
    Yoshiya Horimoto
    Norikazu Masuda
    Touko Inao
    Mitsuchika Hosoda
    Naoko Ishida
    Tomofumi Osako
    Masato Takahashi
    Yumi Endo
    Yuichiro Miyoshi
    Hiroyuki Yasojima
    Nobumoto Tomioka
    Hiroko Yamashita
    Breast Cancer, 2017, 24 : 473 - 482
  • [29] p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer
    Yamashita, Hiroko
    Toyama, Tatsuya
    Nishio, Mariko
    Ando, Yoshiaki
    Hamaguchi, Maho
    Zhang, Zhenhuan
    Kobayashi, Shunzo
    Fujii, Yoshitaka
    Iwase, Hirotaka
    BREAST CANCER RESEARCH, 2006, 8 (04)
  • [30] Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
    Tobin, N. P.
    Harrell, J. C.
    Lövrot, J.
    Egyhazi Brage, S.
    Frostvik Stolt, M.
    Carlsson, L.
    Einbeigi, Z.
    Linderholm, B.
    Loman, N.
    Malmberg, M.
    Walz, T.
    Fernö, M.
    Perou, C. M.
    Bergh, J.
    Hatschek, T.
    Lindström, L. S.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 81 - 88